Spotlight On... SRI pairs with Stanford on discovery project; Aptuit invests in early R&D; and much more...
Global CRO Icon bought a U.S.-based network of clinical research sites, expanding its stateside footprint and bringing in a trove of patient data the company believes will help it to improve study design.
WuXi PharmaTech and PRA Health Sciences are splitting up their China-focused joint venture, preserving an alliance but separating their operations in the country after more than two years of collaboration.
Quintiles, which has signed deep-seated R&D deals with some major players in biopharma, is extending the same all-encompassing development help to the rest of the industry, marketing a service through which the CRO takes a seat at the decisionmaking table.
CRO Charles River Laboratories has expanded its relationship with the Michael J. Fox Foundation for Parkinson's Research to investigate a promising target that could lead to new treatments for the disease.
AMRI, which has backed away from drug discovery in an ongoing restructuring, opened a collaboration-friendly center for early-stage development through a government partnership.
Spotlight On... PSI touts its hematology expertise; Wockhardt clears U.K. regulators; Infinity taps Medidata; and much more...
The rate of employee turnover in the CRO business leapt yet again in 2014, according to a new survey, as companies dial up compensation to retain talent.
A year after INC Research's $150 million IPO, the company's longtime financial supporters are flipping more shares in exchange for $272 million, taking a page from the private equity giants that have profited from the trend of CROs going public.
Parexel International, working through a broad restructuring, said it upgraded its clinical trial management technology to make it scalable for study sponsors of all sizes.
South Korean CRO C&R Research is adopting Medidata's eClinical technology for its trials throughout Asia, striking a partnership to bolster its data analysis technology in a fast-growing market.
U.K. CRO Quotient Clinical has changed private equity hands, as a European healthcare fund co-founded by former Quintiles CEO Dennis Gillings has acquired the company for an undisclosed sum.
Chinese CRO WuXi PharmaTech is on board to help Genomics England pore over samples in its massive project to sequence the genomes of 100,000 Britons.
Charles River Laboratories, on the heels of some M&A-driven revenue growth, acquired another early-stage research company, paying $36 million for a German provider of drug discovery services.
Parexel International, in the midst of sweeping cost cuts, said it has further integrated technology into its drug development services, creating a data-informed process designed to speed up timelines and save money.
PRA Health Sciences is moving into a bigger space in Singapore, consolidating its operations there and looking to boost its share of the growing market for clinical research in Asia.
Quintiles has contributed some open-source code to improve Apple's ResearchKit project, a platform designed to help physicians and scientists gather medical data from millions of patients.
PPD hired a general manager to help grow its Japan-focused joint venture with Shin Nippon Biomedical Laboratories, snagging a Parexel International veteran as it works to expand its presence in a growing market for clinical development services.
Eli Lilly is partnering with CRO WuXi PharmaTech to develop a cholesterol-lowering pill in China, relying on local expertise in hopes of tapping a growing market.
BioDuro, once a division of PDD, has merged with contract manufacturer Formex, expanding its production capabilities in the U.S. while maintaining its research presence in China.